RGLS : Summary for Regulus Therapeutics Inc. - Yahoo Finance

U.S. Markets closed

Regulus Therapeutics Inc. (RGLS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.50+0.10 (+4.17%)
At close: 4:00 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close2.40
Bid2.00 x 100
Ask3.45 x 8000
Day's Range2.32 - 2.50
52 Week Range2.13 - 10.18
Avg. Volume424,615
Market Cap132.31M
PE Ratio (TTM)-1.91
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire12 days ago

    Regulus to Announce New Drug Development Candidates at R&D Day on December 6, 2016

    LA JOLLA, Calif., Nov. 22, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will host a R&D day on Tuesday, December 6, 2016 from 8:30 a.m. to 11:30 a.m. EST in New York City where it plans to announce new development candidates. Interested parties may access a live audio webcast and slides of the presentations on the investor section of Regulus' website at www.regulusrx.com beginning at 8:30 a.m. EST.

  • Capital Cubelast month

    ETF’s with exposure to Regulus Therapeutics, Inc. : November 4, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Regulus Therapeutics, Inc. Here are 5 ETF’s with the largest exposure to RGLS-US. Comparing the performance and risk of Regulus Therapeutics, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Regulus Therapeutics, Inc. :RGLS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
    Capital Cubelast month

    Regulus Therapeutics, Inc. :RGLS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016

    Categories: Yahoo Finance Get free summary analysis Regulus Therapeutics, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Regulus Therapeutics, Inc. – GlaxoSmithKline plc Sponsored ADR, Biogen Inc., Sangamo BioSciences, Inc. and Bristol-Myers Squibb Company (GSK-US, BIIB-US, SGMO-US and BMY-US) that have also reported for this ... Read more (Read more...)